Intra-Cellular Therapies Soars To Multiyear High Following FDA Nod For Schizophrenia DrugBenzinga • 12/23/19
Why This Highflying Biotech Stock Just Rocketed 160% In Massive VolumeInvestors Business Daily • 12/23/19
Intra-Cellular Therapies stock soars 38% premarket after FDA approves schizophrenia treatmentMarket Watch • 12/23/19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in AdultsGlobeNewsWire • 12/23/19
Is the Options Market Predicting a Spike in Intra-Cellular Therapies (ITCI) Stock?Zacks Investment Research • 12/20/19
Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of NeuropsychopharmacologyGlobeNewsWire • 12/12/19
Intra-Cellular Therapies (ITCI) in Focus: Stock Moves 6.1% HigherZacks Investment Research • 12/11/19
Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of NeuropsychopharmacologyGlobeNewsWire • 12/04/19
Options Traders Expect Huge Moves in Intra-Cellular Therapies (ITCI) StockZacks Investment Research • 11/19/19
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?Zacks Investment Research • 09/27/19
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart FailureGlobeNewsWire • 09/25/19